literature

HIV mutation literature information.

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.

PMID: 20030841 2009 AIDS research and therapy

Result: Q151M and L74V were found in 7 (18%) and 2 (5%), respectively.

Table: Q151M

Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.

PMID: 20190870 2009 HIV therapy

Introduction: In addition, three single point mutations, K65R, Q151M and M184V, can confer high-level cross-class resistance to all commercially available NRTIs for HIV-2 infections.

Introduction: Single-genome sequence analysis demonstrates a negative association of K65R with TAMs (T215Y/F + >=2 TAMs) on the same genome, except when facilitated with Q151M complex mutations.

Introduction: The development of K65R and Q151M may be facilitated for HIV-2 variants originating from West Africa (Senegal and Portugal), harboring NNRTI mutations (K101A

The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

PMID: 20190870 2009 HIV therapy

Introduction: In addition, AZT and d4T may also select for the more rarely observed Q151M nucleoside analog mutational (NAM) pathway (Q151M, A62V, V75I, F77L and F116Y), which confers broad-spectra NRTI resistance.

Introduction: The most common coselected mutation is Q151M and the Q151M-NAM resistance pathway, which confers a reduced susceptibility to all NRTIs, with the exception of 3TC and TDF.

Introduction: This second-generation NRTI showed improved antiviral activity against infections harboring TAMs (D67N, K70R and

Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.

PMID: 18272247 2008 Virus research

Abstract: Q151M, M184V, etc.), or (ii) increasing the RT's phosphorolytic activity (e.g.

Chemical system biology based molecular interactions to identify inhibitors against Q151M mutant of HIV-1 reverse transcriptase.

PMID: 18277921 2008 The Pediatric infectious disease journal

Abstract: We report the first case of mother-to-child transmission of human immunodeficiency virus type 1 strains harboring multiple mutations including the Q151M multinucleoside reverse transcriptase inhibitor resistance mutation.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

PMID: 18304321 2008 BMC infectious diseases

Abstract: Within RT, they were M184V, Q151M, V111I and K65R.

Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues.

PMID: 18389906 2008 Antiviral therapy

Abstract: Interactions between the Gln151 residue and the methyl group of tenofovir-DP further increase with the mutation Gln151Met, resulting in a specific discrimination and low-level resistance to tenofovir-DP.

2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

PMID: 18487070 2008 The international journal of biochemistry & cell biology

Abstract: EFdA retains potency toward many HIV-1 resistant strains, including the multi-drug resistant clone HIV-1A62V/V75I/F77L/F116Y/Q151M.

Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.

PMID: 18662701 2008 Journal of molecular biology

Abstract: Common mutational patterns involve the deletion of Asp67 (Delta 67) and mutations such as K70R and T215F or T215Y, or the deletion of Thr69 (Delta 69) and mutations of the Q151M complex.

Abstract: Human immunodeficiency virus type 1 clones containing Delta 69 in a multidrug-resistant sequence background, including the Q151M complex and substitutions K103N, Y181C, M184V, and G190A, showed high-level resistance to all tested nucleoside RT inhibitors.

Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

PMID: 18838582 2008 Antimicrobial agents and chemotherapy

Abstract: Due to codon usage variation, there is a significantly lower incidence of the substitutions L210W, Q151M, and F116Y in subtype F1 isolates than in the subtype B counterparts.

Browser Board

Co-occurred Entities

Filtrator